Taysha Gene Therapies Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, and thank you for joining us today. My name is [Fauci Kash], and I'm an analyst at JPMorgan Selfcare Group. Before we get started, I just wanted to note that there will be no Q&A for the session. And with that, I'll pass it over to our speakers, RA Session, President, CEO and Founder of Taysha Gene Therapies; and Suyash Prasad, Medical Officer and Head of R&D.
Thanks, [Fauci]. Good morning, everyone. Thank you, guys, for having us this morning. I'm happy to be presenting an initial overview of our story. I'll just start with some forward-looking statements here. And here's a summary of the company really why we're so excited about what lies ahead for 2022, just starting with a couple of near-term value inflection points. We'll be reporting long-term durability and long-term safety data on our high-dose cohorts and our other therapeutic doses, from our lead program, TSHA-120 giant axonal neuropathy later this month.
We'll also be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
